Hero image with Pittsburgh background pittplusme.org/study/1598

Pitt+Me HCC 19-042: COSMIC-313 Study


STUDY BASICS

Do you have kidney cancer (renal cell carcinoma) that is advanced or has spread to other parts of your body, and have not yet been treated? If so, you may be interested in a study to see whether a combination of two investigational new drugs is safe and effective in slowing down the growth of your kidney cancer.


IRB:
  20190770 - A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk

Age Range
AGE:   18 and Up

Duration DURATION:  15-21 months
VISITS:  Multiple

Location LOCATION: 
UPMC Cancer Center locations in Shadyside, Arnold Palmer Pavilion-Greensburg, Monroeville, Passavant, Upper St. Clair
Compensation COMPENSATION: 

None

Phone Number PHONE NUMBER:
1-866-438-8230
I'M INTERESTED
SHARE STUDY
Printer Printer   Email A FriendEmail A Friend   ShareShare   TweetTweet   Linked-InLinked-In
Search Icon pittplusme.org/study/1598
OR
Phone Number PHONE NUMBER:
1-866-438-8230

PittPlusMe.org 1-866-438-8230 PittPlusMe@pitt.edu
@PittPlusMe share tweet

Pitt+Me

This website is maintained by the Clinical and Translational Science Institute.
© Copyright 2018, University of Pittsburgh. All rights reserved.